Followers | 4053 |
Posts | 151231 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Tuesday, December 01, 2015 7:36:20 AM
United States Patent and Trademark Office Grants Patent for Vectra(R) DA
Alert
Myriad Genetics (NASDAQ:MYGN)
Intraday Stock Chart
Today : Tuesday 1 December 2015
Click Here for more Myriad Genetics Charts.
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection for Crescendo Bioscience's Vectra® DA testing.
Crescendo Bioscience logo
Vectra DA is an advanced blood test for adults with rheumatoid arthritis (RA) and helps patients objectively track their disease activity over time. Vectra DA measures expression levels of twelve biomarkers that are then combined into a single score. The twelve biomarkers measured by Vectra DA are: VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, leptin, resistin, SAA and CRP.
The recently issued patent is co-assigned to Crescendo and the Oklahoma Medical Research Foundation and is the first patent issued relating to Vectra DA. Crescendo will continue to pursue additional patent applications, which if issued, should expand the scope of intellectual property protection for Vectra DA.
"Crescendo's first patent for Vectra DA is significant because it validates the innovation required to bring to market the only objective multi-biomarker test for assessing RA disease activity," said Bernie Tobin, president, Crescendo Bioscience. "The PTO's decision comes at a critical time as we enter the golden era of personalized medicine. In order for personalized medicine to become a reality, strong intellectual property protection is essential because it provides research-based companies like Crescendo with incentives to continue to invest in research and development."
About Vectra® DA
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit: www.Vectra-DA.com.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, Calif. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at www.CrescendoBio.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
Recent MYGN News
- Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen • GlobeNewswire Inc. • 04/16/2024 01:15:00 PM
- Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date • GlobeNewswire Inc. • 03/22/2024 01:40:00 AM
- Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device • GlobeNewswire Inc. • 03/20/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:18:02 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 01:31:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:47 PM
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fo • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 • GlobeNewswire Inc. • 02/27/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:12:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:09:56 PM
- Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/21/2024 09:05:00 PM
- Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health • GlobeNewswire Inc. • 02/15/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:47:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:24:26 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/08/2024 03:14:32 PM
- Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics • GlobeNewswire Inc. • 02/01/2024 02:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:15:23 PM
- Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology • GlobeNewswire Inc. • 01/30/2024 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 09:27:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 09:21:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:31:19 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/22/2024 07:03:13 PM
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics • GlobeNewswire Inc. • 01/18/2024 11:10:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM